The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

A donut-eating contest helped raise funds for 17-year-old Levi Atkins, who's battling Acute Myeloid Leukemia, while uniting ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...

Moleculin Biotech (MBRX) announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia. This includes data from preclinical in vitro studies ...

The University of Connecticut’s athletic department will host four separate bone marrow registry drives throughout November. The drives were organized in honor of 8-year-old Ben Rabinowitz, who was ...

Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to Venetoclax. Recent preclinical studies and preliminary clinical ...

Brisa Aschebrook-Kilfoy, Associate Professor of Family Medicine at UChicago, is an expert in conducting environmental exposure assessments. She is actively leading efforts to build resources to study ...

"When you know that your granddaughter, who at that point wasn't even a year old, has already done that treatment, it made me ...

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) has been assigned an average rating of “Hold” from the five ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of ...